Abstract: An amplifying apparatus includes a first amplifier that amplifies an input signal on the basis of a value of a drain voltage and outputs a transmission signal, a distortion compensator that corrects a power amplitude of the input signal on the basis of a difference in power amplitude between the input signal and the transmission signal outputted from the first amplifier, a drain voltage controller that generates the drain voltage on the basis of the power amplitude of the input signal to be corrected, and a drain voltage corrector that corrects the drain voltage on the basis of the difference.

Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Abstract: The disclosed image forming apparatus includes a rotatable image holding body configured to hold an electrostatic latent image on a surface of the image holding body, a developing device including a forward rotation developing roller rotatable in a same rotational direction as that of the rotatable image holding body and a reverse rotation developing roller rotatable in a reverse rotational direction to that of the rotatable image holding body, which supply a two-component developer to the surface of the image holding body to form a toner image corresponding to the electrostatic latent image, and a control unit configured to control rotation of the image holding body, the forward rotation developing roller, and the reverse rotation developing roller to supply the two-component developer. The control unit controls the rotation of the image holding body to start after a predetermined time period from starting the rotation of the forward rotation developing roller and the reverse rotation developing roller.

Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.

Abstract: An amplifying device includes an amplifier including a first amplifying element with a drain voltage thereof being controlled, and a second amplifying element, the amplifier amplifying a transmission signal with the first and second amplifying elements, synthesizing the transmission signals amplified by the first and second amplifying elements, and outputting the synthesized transmission signal; a distortion compensator part which performs distortion compensation on the input signal in accordance with a compensation coefficient derived from a difference between a input signal and a feedback signal generated from a portion of a signal output from the amplifier; and a controller part which controls the drain voltage of the first amplifying element in response to a result of a comparison between a power level of the input signal prior to the distortion compensation operation by the distortion compensator part and a threshold value.

Abstract: A power amplifying apparatus has a GaN device for RF amplification, a GaN device for monitoring, an Idq detecting circuit, and a gate bias control (GBC) circuit. The GaN device for RF amplification amplifies an input signal to output the resultant. The GaN device for monitoring is an amplification device for monitoring an input/output signal of the GaN device for RF amplification. The Idq detecting circuit detects an output signal output by the GaN device for monitoring, corresponding to an input signal, which is diverged from the input signal to be input to the GaN device for RF amplification, and is input to the GaN device for monitoring. The gate bias control circuit controls a gate voltage to be applied to the GaN device for RF amplification in accordance with the output signal detected by the Idq detecting circuit.

Abstract: An image forming apparatus includes a first image formation unit that forms a black toner image, and a detachable second image formation unit that forms a color toner image. A first toner supply unit is provided to supply the black toner to the first image formation unit. A second toner supply unit is provided to supply one of a black and component color toner to the first and second image formation units in accordance with a color mode. A first conveyance path is provided to convey the black toner to the first image formation unit. A second conveyance path is also provided to convey the component color toner stored in the second toner container section to the second image formation unit. The second toner supply unit is selectively connected to one of the first and second conveyance paths in accordance with the color mode.

Abstract: When genes encoding three kinds of proteins constituting fibrinogen, an ? chain (or variant of ? chain), a ? chain and a ? chain (or variant of ? chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a ? chain (and/or variant of ? chain) gene is an equal amount to a 1000-fold amount relative to an ? chain (and/or variant of ? chain) gene and a ? chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared.

Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Abstract: An amplifying apparatus includes a first amplifier that amplifies an input signal on the basis of a value of a drain voltage and outputs a transmission signal, a distortion compensator that corrects a power amplitude of the input signal on the basis of a difference in power amplitude between the input signal and the transmission signal outputted from the first amplifier, a drain voltage controller that generates the drain voltage on the basis of the power amplitude of the input signal to be corrected, and a drain voltage corrector that corrects the drain voltage on the basis of the difference.

Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.

Abstract: A process for preparing an inclusion body-forming protein is provided.

Abstract: An amplifier failure detection apparatus for a radio transmitter that has a function for compensating for amplifier distortion of the radio transmitter and a function for determining amplifier failure has occurred by detecting that the gain of an amplifier has dropped a set level or more, in which: a gain-detection unit detects the gain of the amplifier; an alarm-detection-level-generation unit, which has a table for storing alarm-detection levels that correspond to input-amplitude levels, generates an alarm-detection level that corresponds to an input-amplitude level; and a comparison unit compares the gain detected by the gain-detection unit with the alarm-detection level, and generates an alarm based on the comparison results.

Abstract: The present invention is a bacteriolytic agent containing a cationic surfactant (A) of which a counteranion is an acid having a pKa (25° C.) of 0 to 10. As the counterion, a carboxylate anion is preferable. As the cationic surfactant (A), a quaternary ammonium salt-type surfactant is preferable. Examples of the useful substance include a protein, an amino acid, a nucleic acid, an antibiotic, sugars or vitamins. The bacteriolytic agent of the present invention is excellent in a bacteriolytic power in a step of extracting a useful substance from a microorganism (useful substance producing bacterium etc.). In addition, denaturation of the useful substance during the step is small.

Abstract: A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for ameliorating neurotransmission dysfunction diseases caused by various pathological conditions is provided.

Abstract: A blood-viscosity reducing agent contains a protein derived from Bacillus subtilis natto and including, sequentially from an amino group terminal, a first structural amino acid sequence having alanine, threonine, aspartic acid, glycine, valine, glutamic acid, tryptophan, asparagine, valine, aspartic acid, glutamine, isoleucine, aspartic acid, alanine, proline, lysine, alanine, tryptophan, alanine, leucine, glycine, tyrosine aspartic, acid, glycine, threonine, glycine, threonine, valine, valine, alanine, serine, isoleucine, aspartic acid, threonine, glycine, valine, glutamic acid, tryptophan, asparagine, histidine, proline, alanine, leucine, lysine, glutamic acid, lysine, tyrosine, arginine, glycine, tyrosine, asparagine, proline, glutamic acid, asparagine, proline, asparagine, glutamic acid, proline, glutamic acid, asparagine, glutamic acid, methionine, asparagine, tryptophan, tyrosine, aspartic acid, alanine, valine, alanine, glycine, glutamic acid, alanine, serine, proline, tyrosine, aspartic acid, aspartic

Abstract: A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.

Abstract: There is provided a filter which includes a transmission line, a stub branched from the transmission line, the stub electrically coupled with the transmission line, and a resonator configured to electromagnetically couple with the stub and to resonate at an odd harmonic frequency of a fundamental wave, the fundamental wave propagating through the transmission line.

Abstract: An image forming apparatus includes a first image formation unit that forms a black toner image, and a detachable second image formation unit that forms a color toner image. A first toner supply unit is provided to supply the black toner to the first image formation unit. A second toner supply unit is provided to supply one of a black and component color toner to the first and second image formation units in accordance with a color mode. A first conveyance path is provided to convey the black toner to the first image formation unit. A second conveyance path is also provided to convey the component color toner stored in the second toner container section to the second image formation unit. The second toner supply unit is selectively connected to one of the first and second conveyance paths in accordance with the color mode.

Abstract: An image forming apparatus including a conveyance unit to convey a transfer medium, a first image forming unit to form a monochrome image transferred at a first transfer position onto the transfer medium, and a second image forming unit disposed downstream from the first image forming unit in a direction of conveyance of the transfer medium, including an intermediate transfer body to form a multi-colored toner image on the intermediate transfer body. The multi-colored toner image is transferred onto the transfer medium at a second transfer position. The conveyance unit is separated from the intermediate transfer body at the second transfer position in a monochrome mode to form the monochrome image using only the first image forming unit, and contacts the intermediate transfer body at the second transfer position in a full-color mode to form a full-color image using both the first and second image forming units.